Quoin Pharmaceuticals Initiates QRX003 Trial in New Zealand for Peeling Skin Syndrome

The speciality pharmaceutical business Quoin Pharmaceuticals has announced that a clinical research headed by an investigator would begin in New Zealand to assess the safety and effectiveness of QRX003, its medication, in a paediatric patient with Peeling Skin Syndrome (PSS). In two late-stage clinical trials, QRX003 is presently being assessed as a possible therapy for Netherton Syndrome (NS) in the United States. Under an active Investigational New Drug (IND) application filed with the FDA, both investigations are being carried out. Peeling skin condition is the second indication for QRX003, and Quoin is thrilled to see it progress towards bettering this terrible illness.

As of right now, peeling skin syndrome has no authorised therapy or cure and no clinical trials mentioned on clinicaltrials.gov. This gives Quoin the chance to become the first company to receive regulatory clearance for a different uncommon genetic illness. A novel "whole body, whole life" topical lotion, QRX003 addresses disturbance of the skin's barrier and inflammation.